Emerging biological therapies for the treatment of myelodysplastic syndromes.

Emerging biological therapies for the treatment of myelodysplastic syndromes.

Item
http://www.wikidata.org/entity/Q38834981
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
P2860

Emerging biological therapies for the treatment of myelodysplastic syndromes.

Item
http://www.wikidata.org/entity/Q38834981
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Emerging biological therapies for the treatment of myelodysplastic syndromes.
@en
type
label
Emerging biological therapies for the treatment of myelodysplastic syndromes.
@en
prefLabel
Emerging biological therapies for the treatment of myelodysplastic syndromes.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Emerging biological therapies for the treatment of myelodysplastic syndromes.
@en
P2093
P2860
P304
P31
P356
10.1080/14728214.2016.1220534
P407
P433
P478
P577
P698